GANX
Gain Therapeutics, Inc.NASDAQHealthcare$1.85+0.54%ClosedMarket Cap: $78.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.30
P/S
0.00
EV/EBITDA
-3.14
DCF Value
$0.61
FCF Yield
-23.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-237.5%
ROA
-88.4%
ROIC
-95.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-4.5M | $-4.5M | $-0.11 | — |
| FY 2025 | $0.00 | -Infinity% | $-18.7M | $-20.2M | $-0.61 | — |
| Q3 2025 | $0.00 | -Infinity% | $-4.8M | $-5.3M | $-0.15 | — |
| Q2 2025 | $0.00 | -Infinity% | $-5.1M | $-5.8M | $-0.19 | — |
| Q1 2025 | $0.00 | -Infinity% | $-4.4M | $-4.5M | $-0.16 | — |
| Q4 2024 | $0.00 | -Infinity% | $-3.3M | $-3.8M | $-0.14 | — |
| FY 2024 | $0.00 | NaN% | $-20.4M | $-20.4M | $-0.89 | — |
| Q3 2024 | $0.00 | -Infinity% | $-4.5M | $-4.5M | $-0.17 | — |
| Q2 2024 | $0.00 | -Infinity% | $-8.2M | $-8.1M | $-0.42 | — |
| Q1 2024 | $0.00 | -Infinity% | $-4.4M | $-4.0M | $-0.22 | — |
| Q4 2023 | $0.00 | -Infinity% | $-4.4M | $-4.7M | $-0.29 | — |
| FY 2023 | $55.2K | 100.0% | $-22.3M | $-22.3M | $-1.71 | — |